ATE325606T1 - Dosisform mit ansteigender dosisfreisetzung - Google Patents

Dosisform mit ansteigender dosisfreisetzung

Info

Publication number
ATE325606T1
ATE325606T1 AT97947642T AT97947642T ATE325606T1 AT E325606 T1 ATE325606 T1 AT E325606T1 AT 97947642 T AT97947642 T AT 97947642T AT 97947642 T AT97947642 T AT 97947642T AT E325606 T1 ATE325606 T1 AT E325606T1
Authority
AT
Austria
Prior art keywords
dose
rising
release
dose form
release dose
Prior art date
Application number
AT97947642T
Other languages
German (de)
English (en)
Inventor
Lawrence G Hamel
Atul Devdatt Ayer
Jeri D Wright
Andrew Lam
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26707551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE325606(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE325606T1 publication Critical patent/ATE325606T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97947642T 1996-11-25 1997-11-12 Dosisform mit ansteigender dosisfreisetzung ATE325606T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3174196P 1996-11-25 1996-11-25
US96760697A 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
ATE325606T1 true ATE325606T1 (de) 2006-06-15

Family

ID=26707551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947642T ATE325606T1 (de) 1996-11-25 1997-11-12 Dosisform mit ansteigender dosisfreisetzung

Country Status (11)

Country Link
EP (1) EP0946151B1 (enExample)
JP (2) JP5173089B2 (enExample)
CN (2) CN100477986C (enExample)
AT (1) ATE325606T1 (enExample)
AU (1) AU5267698A (enExample)
CA (1) CA2265668C (enExample)
DE (1) DE69735848T2 (enExample)
DK (1) DK0946151T3 (enExample)
ES (1) ES2264173T3 (enExample)
PT (1) PT946151E (enExample)
WO (1) WO1998023263A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
EA005537B1 (ru) 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
WO2003057136A2 (en) 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20100151020A1 (en) 2008-12-16 2010-06-17 Vered Rosenberger Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
AU652952B2 (en) * 1990-07-23 1994-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
ATE183642T1 (de) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.

Also Published As

Publication number Publication date
CA2265668A1 (en) 1998-06-04
HK1021620A1 (en) 2000-06-23
JP2010215632A (ja) 2010-09-30
CN1182839C (zh) 2005-01-05
PT946151E (pt) 2006-07-31
DK0946151T3 (da) 2006-08-28
CN100477986C (zh) 2009-04-15
DE69735848T2 (de) 2006-12-28
CN1636552A (zh) 2005-07-13
EP0946151B1 (en) 2006-05-10
CA2265668C (en) 2005-08-23
ES2264173T3 (es) 2006-12-16
DE69735848D1 (de) 2006-06-14
EP0946151A1 (en) 1999-10-06
JP2002513392A (ja) 2002-05-08
JP5173089B2 (ja) 2013-03-27
AU5267698A (en) 1998-06-22
WO1998023263A1 (en) 1998-06-04
JP5215347B2 (ja) 2013-06-19
CN1233953A (zh) 1999-11-03

Similar Documents

Publication Publication Date Title
ATE325606T1 (de) Dosisform mit ansteigender dosisfreisetzung
DK0932388T3 (da) Doseringsform og fremgangsmåde til indgivelse af lægemidler
DE69720055D1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
NO20006007D0 (no) Fremgangsmåte til dosering av et medikament, samt doseringsform
DK0663825T3 (da) Anvendelse af melatonin i orale doser til fremkaldelse af søvn
FI971188L (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
ATE200025T1 (de) Flüssige arzneizubereitungen enthaltend schilddrüsenhormone
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
NO923769D0 (no) System for iontoforetisk tilfoersel av et medikament
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
DE59808186D1 (de) Transdermales therapeutisches system zur abgabe von hormonen
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE60019334D1 (de) Antivirale arznei
PL328924A1 (en) Method of treating abuse of substances
SE9101341D0 (sv) New medicinal use
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
ZA977873B (en) Dosage form and method for administering drug.
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
EP1690531A3 (en) Dosage form and method for administering drug
MX9709013A (es) Forma de dosis que comprende oxibutinina.
MX9605190A (es) Forma de dosis efectiva para farmacos antiepilepticos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946151

Country of ref document: EP